Effect of Grapes in Inflammatory Bowel Disease

Sponsor
Case Western Reserve University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05972694
Collaborator
California Table Grape Commission (Other)
20
1
18

Study Details

Study Description

Brief Summary

The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Freeze dried grape powder
N/A

Detailed Description

This protocol is designed to investigate the effect of grape powder consumption in Inflammatory Bowel Disease (IBD), in particular how grape powder consumption (provided as 46g/day grape powder; equivalent to 1.5 cups fresh grapes) alters the gut microbiota (GM) composition in humans with IBD. The investigators will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions).

The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the GM composition in adult patients with the IBD subtype Crohn's disease (CD).

An 8-week pilot study in adult CD patients at the Digestive Health Institutes (DHI) of University Hospitals Cleveland Medical Center (UHCMC). table

Participation in this study will last for a maximum of 56 days and will consist of two phases. Phase I (baseline period - 21-28 days) where all grapes and berries will be removed from the diet, and Phase II (intervention period - 28 days) where participants will be supplemented with 46g/d freeze-dried grape powder consumed as 22.5g packets twice daily. The dose of 46g/day of grape powder is equivalent to 1.5 cups of grapes. Participants will be asked to avoid consumption of all other grapes/berries during phase II. The investigators will compare the before and after changes in gut microbiota composition.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
subjects will continue to consume their usual diet (excluding all grapes/berries) and consume 46g/d freeze-dried grape powder daily (consumed as 22.5g packets twice daily for 28 days. A stool, urine and blood sample will be collected at the start and end of the intervention..subjects will continue to consume their usual diet (excluding all grapes/berries) and consume 46g/d freeze-dried grape powder daily (consumed as 22.5g packets twice daily for 28 days. A stool, urine and blood sample will be collected at the start and end of the intervention..
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The Effect of Grapes in Inflammatory Bowel Disease
Anticipated Study Start Date :
Apr 2, 2024
Anticipated Primary Completion Date :
Jun 2, 2025
Anticipated Study Completion Date :
Oct 2, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Freeze-dried Grape powder intervention

participants will be supplemented with 46g/d freeze-dried grape powder consumed as 22.5g packets twice daily for 28 days.

Dietary Supplement: Freeze dried grape powder
46g/d freeze-dried grape powder

Outcome Measures

Primary Outcome Measures

  1. fecal microbiota composition [baseline (pre-intervention), immediately after the intervention]

    16S microbiome

Secondary Outcome Measures

  1. fecal myleoperoxidase (MPO) [baseline (pre-intervention), immediately after the intervention]

  2. fecal calprotectin [baseline (pre-intervention), immediately after the intervention]

  3. Crohns Disease Activity Index [baseline (pre-intervention), immediately after the intervention]

  4. C-reactive protein (CRP) [baseline (pre-intervention), immediately after the intervention]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Documented diagnosis of Crohns disease. CD outpatients in remission

  • Harvey Bradshaw-index in remission (<5 score)

  • Capable of providing consent to participate.

  • Able to complete daily surveys and take oral nutrition

  • Able to record daily meal intake

Exclusion Criteria:
  • Short bowel syndrome.

  • Hospitalized patients.

  • Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients.

  • Known drug abuse.

  • Known parasitic disease of the digestive system.

  • Symptomatic intestinal stricture.

  • Presence of an ostomy.

  • Other conditions that would be a contraindication to consumption of the study diets or preclude the participant from completing the study.

  • Well-founded doubt about the patients cooperation.

  • Existing pregnancy or lactation.

  • History of <1 natural bowel movements per day.

  • Unable to access to technology that permits the daily completion of study related activities.

  • Change in IBD medication within past 4 weeks.

  • Body mass Index <16 kg/m or ≥35.

  • Documented C.difficile colitis within four weeks of screening.

  • Known berry or grape allergy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Case Western Reserve University
  • California Table Grape Commission

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Abigail Basson, Principal Investigator, study coordinator, Case Western Reserve University
ClinicalTrials.gov Identifier:
NCT05972694
Other Study ID Numbers:
  • STUDY20230070
First Posted:
Aug 2, 2023
Last Update Posted:
Aug 2, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2023